Project Grant R01HL181024
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $818,279 to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct research on improving the subtyping and characterization of obstructive sleep apnea (OSA). The project will leverage data from existing research cohorts and a clinical biobank to quantify the reproducibility of OSA severity markers and derive physiologically...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to elucidate the complex relationship between obstructive sleep apnea (OSA) and cardiovascular disease (CVD). The $1,296,660 award supports a 24-month research project that will employ a "bed to bench" approach integrating clinical, computational, and in vitro techniques. Key objectives include developing and validating a mathematical model to quantify...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $816,472 project grant to the Icahn School of Medicine at Mount Sinai (ISMMS). The grant, awarded on August 1, 2025 and set to conclude on May 31, 2029, aims to enhance cardiovascular risk prediction and treatment response in obstructive sleep apnea (OSA) patients using advanced AI-based transformer models and multi-modal sleep data. The project will...
- The U.S. National Heart Lung and Blood Institute awarded a $316,609 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Remastered Sleep LLC for the development of a "Novel Myofunctional Nipple to Prevent Obstructive Sleep Apnea in Infants." The project aims to address the clear unmet need for a non-invasive, first-line treatment and preventive measure for obstructive sleep apnea (OSA) in infants, which can have detrimental long-term health impacts...
- This federal Project Grant award of $761,028 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research will support a multi-site prospective study on hypoxemia during sleep in adults with sickle cell anemia (SCA). The study aims to examine the prevalence, clinical impact, and response to treatment of sleep-related hypoxemia in this patient population across four institutions, including both urban and rural sites. Key activities will involve...
- This $782,473 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to improve understanding of the pathogenesis of sleep apnea using novel imaging techniques during sleep. The project aims to characterize the site and pattern of airway collapse as well as how upper airway anatomy mediates this collapse, which could provide new insights to guide optimal therapies, particularly for patients who cannot tolerate...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $583,718 Project Grant to Berendo Scientific LLC under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize and evaluate the SLEEPFLEX head and neck exercise program for the treatment of mild to moderate obstructive sleep apnea (OSA). The project aims to develop a focused, effective, safe, and non-invasive head and neck exercise program delivered via a smartphone app to increase the strength and endurance of key...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,415,112 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nebraska Medical Center (UNMC) to evaluate a telehealth-delivered adaptive intervention for improving continuous positive airway pressure (CPAP) therapy adherence and health outcomes in adults with obstructive sleep apnea (OSA). The project aims to: 1) compare effects of motivational enhancement, device support, and...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will validate a new, minimally invasive cervical surgical approach to phrenic nerve stimulation for the treatment of central sleep apnea (CSA). The $982,086 project, awarded to Coridea, LLC, a medical technology firm in New York, aims to develop a simplified procedure that can be performed in an outpatient setting by ENT surgeons, as the current commercially...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $644,687 to the University of Missouri System to conduct research on a neural circuit in the brain that contributes to hypertension associated with obstructive sleep apnea. The research aims to determine how this "orexin-CRH-NTS" circuit facilitates the peripheral chemoreflex and leads to sympathoexcitation and hypertension,...
The National Heart, Lung, and Blood Institute (NHLBI), under CFDA program 93.837 "Cardiovascular Diseases Research", awarded a $1,270,508 Project Grant to the Northern California Institute for Research and Education, Inc. (NCIRE) on September 20, 2025. The grant funds a project titled "Improving Identification of Obstructive Sleep Apnea in Women" that aims to: 1) Identify health factors associated with obstructive sleep apnea in women using electronic health records and survey data, 2) Develop a novel, sex-tailored screening instrument to identify women with obstructive sleep apnea, and 3) Test the accuracy of the new screening instrument in a national sample of adult women. The project seeks to address the critical need to improve understanding, identification, and diagnosis of obstructive sleep apnea in women, as it is estimated that over 98% of women with this condition remain undiagnosed.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 9/20/25 |